头癌患者在治疗化疗或放射治疗后两年出现晚期癌症缓解症
Willian das Neves1, Thomás Giollo Rivelli1, Eduardo Furquim Simão1
1Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.
Clinics (Sao Paulo, Brazil)
|December 22, 2025
概括
缓解期的头癌患者仍然经常经历缓解症,一种消耗综合征. 这项研究发现,治疗后两年,超过20%的幸存者患有白血病,影响肌肉质量和力量.
科学领域:
- 在瘤学瘤学.
- 营养科学 营养科学
- 临床研究 临床研究
背景情况:
- 头部和部状细胞癌 (HNSCC) 占头部和部癌症的90%以上.
- 在HNSCC治疗后没有疾病证据的患者经常面临长期毒性.
- 晚期的毒性会对生活质量和生存率产生重大影响.
研究的目的:
- 为了确定HNSCC患者中白血病的患病率.
- 在治疗意图的基斯普拉丁基化学辐射治疗后,在没有疾病迹象的患者中评估缓解症.
- 在这个人群中探索缓解症和失消症之间的关联.
主要方法:
- 120名HNSCC患者的横截面观察研究.
- 纳入标准:至少2年的随访,没有疾病后化学辐射的证据.
- 评估临床特征,身体组成,肌肉强度,营养状况和血液检查.
主要成果:
- 在治疗后的两年内,白内障患病率为20.7% (费伦标准) 和8.6% (埃文斯标准).
- 卡赫西克症患者的中臂肌肉周长减少.
- 低肌肉强度被观察到在卡赫西克患者 (埃文斯标准);没有发现失调-卡赫西克的关联.
结论:
- 在长期随访的HNSCC幸存者中,白内障是常见的疾病.
- 没有疾病治疗后化学辐射的证据的患者仍然面临着缓冲症的风险.
- 这些发现突显出需要监测和管理HNSCC存活率中的缓解症.
相关概念视频
Cancer Survival Analysis
626
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
626
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
516
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
516


